Founded in 2014 and located in the vibrant Medtech ecosystem in Montpellier, France, Sim&Cure is a digital start-up focused on Improving patient outcome and physician experience of endovascular treatment by combining Digital Twin and AI Technologies.
As new technologies progress through the medical network, S&C will help its partners to flatten the learning curve. Sim&Cure’s philosophy focuses on driving innovation in the healthcare industry and helping to improve treatments strategies in order to secure patient care.
Sim&Cure has established scientific and clinical collaborations with leading laboratories and hospitals around the world.
Sim&Cure’s geographic scaling began in the US with the opening of a subsidiary in NY in July 2019 and will continue in 2024 in the Asia zone and more particularly China.
Sim&Cure counts among its customers the largest Medtech groups such as Medtronic, Stryker or Terumo among others, with the mission of securing patient treatment.
Sim&Cure’s ambition is to become a standard in patient care insofar as it will become essential to carry out a digital therapeutic planning before each endovascular intervention.
The company employs 65 people and anticipates a phase of strong growth.